US Patent 11446387 Compositions and methods of treating muscle dystrophy

Is a

Patent

Patent attributes

Patent Applicant

Avidity Biosciences

Current Assignee

Avidity Biosciences

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

114463870

Date of Patent

September 20, 2022

Patent Application Number

172145250

Date Filed

March 26, 2021

Patent Citations

‌

US Patent 10881743 Compositions and methods of treating muscle atrophy and myotonic dystrophy

‌

US Patent 11028179 Anti-transferrin receptor antibodies and uses thereof

‌

US Patent 10000754 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

‌

US Patent 10323089 Anti-transferrin receptor antibodies with tailored affinity

‌

US Patent 10913800 Anti-transferrin receptor antibodies and uses thereof

Patent Citations Received

‌

US Patent 11872287 Compositions and methods of treating muscle atrophy and myotonic dystrophy

‌

US Patent 11707532 Compositions and methods of treating muscle dystrophy

Patent Primary Examiner

‌

Tracy Vivlemore

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 11446387 Compositions and methods of treating muscle dystrophy

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 11446387 Compositions and methods of treating muscle dystrophy